Organization (Industry)
SOLVENTUM US LLC
ClinicalTrials.gov lists SOLVENTUM US LLC as lead sponsor of 64 trials. It has 5 active development programs and 10 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Solventum, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers SOLVENTUM US LLC: 64 lead-sponsored trials and 2 legal-entity registrations. Part of Solventum Corp.
Disease areas (33)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dental Caries | 10 |
| Respiratory Aspiration | 4 |
| Surgical Wound Infection | 3 |
| Varicose Ulcer | 3 |
| Varicose Veins | 3 |
Showing 5 of 33 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 4 |
Showing 10 of 21 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (5)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Tiotropium | Respiratory Aspiration | Phase 1 | 3 |
| tiotropium pMDI | Respiratory Aspiration | Early 1 | 1 |
| flowable composite | Bicuspid Aortic Valve Disease | Not reported | 1 |
| flowable composite | Dental Caries | Not reported | 1 |
| flowable composite | Heart Defects, Congenital | Not reported | 1 |
Approved assets (10)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| ChloraPrep | 3 |
| Purell Surgical Scrub | 1 |
| Alcohol hand sanitizer foam | 1 |
| DuraPrep | 1 |
| Mupirocin calcium ointment, 2% | 1 |
Showing 5 of 10 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 25% hit target (n=20) | 47% on time (n=19) |
Journals published in (55)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of infusion nursing : the official publication of the Infusion Nurses Society | 5 |
| Infection control and hospital epidemiology | 3 |
| International wound journal | 3 |
| Operative dentistry | 3 |
| Acta odontologica Scandinavica | 2 |
Showing 5 of 55 journals.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 3 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2026-05-07 |
Manufacturing and distribution sites (7)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Solventum US LLC | Flemington, US | FDA | |
| Solventum US LLC | Columbia, US | FDA | |
| SOLVENTUM US LLC | Eagan, US | FDA | |
| Solventum US LLC | Brookings, US | FDA | |
| Solventum US LLC | Eden Prairie, US | FDA |
Showing 5 of 7 sites.
Latest dated events (68)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-07 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-02-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-01-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 68 events.
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| FGF7 | Trial sponsor | Named in trial exclusion criteria |
| PTGS2 | Trial sponsor | Named in trial exclusion criteria |
| FGF7 | Trial sponsor | Mentioned in trial text |
| PTGS2 | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.